BLAINJECTIONINJECTABLE
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
46
Data completeness
4/8 — Partial
ADCETRIS (brentuximab vedotin) by Pfizer is cd30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of salcl cells and on hodgkin reed-sternberg (hrs) cells in chl. First approved in 2011.
Drug data last refreshed 34m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) that binds to CD30 on lymphoma cells and delivers a microtubule-disrupting agent (MMAE) intracellularly, inducing apoptosis. It is approved for Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL), with activity in other CD30-expressing T-cell lymphomas. The mechanism leverages both targeted cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
$0.003BPart D
PeakADCETRIS is at peak commercial maturity with established market presence; R&D and Supply Chain roles indicate ongoing optimization and manufacturing scale demands.
Mechanism of Action
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (46)
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
Started Jul 2026
46 enrolled
Cutaneous T-Cell Lymphoma/Mycosis FungoidesPrimary Cutaneous Anaplastic Large Cell Lymphoma
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Started Feb 2026
100 enrolled
CD30-Positive Peripheral T-Cell Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Started Aug 2024
124 enrolled
Hodgkin Lymphoma
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Started Feb 2024
3 enrolled
Diffuse Cutaneous Systemic Sclerosis
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
Started Feb 2024
26 enrolled
T-Cell Lymphoma
Worked on ADCETRIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.